Nasdaq apls.
The chart below shows the one year performance of APLS shares: Looking at the chart above, APLS's low point in its 52 week range is $42.15 per share, with $94.75 as the 52 week high point — that ...
Nov 2, 2023 · Reported EPS is $-1.17 EPS, expectations were $-0.86. Operator: Good morning ladies and gentlemen. Thank you for standing by and welcome to the Apellis Pharmaceuticals Third Quarter 2023 Earnings ... The public float for APLS is 97.66M, and at present, short sellers hold a 16.62% of that float. On November 16, 2023, the average trading volume of APLS was 2.69M shares. APLS) stock’s latest price update. Apellis Pharmaceuticals Inc (NASDAQ: APLS)’s stock price has plunge by 0.54relation to previous closing price of 48.14.WALTHAM, Mass., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company ...WALTHAM Mass. and CRESTWOOD, Ky., March 06, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel ...
Apellis Pharmaceuticals, Inc. Common Stock (APLS) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets.
WALTHAM, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its fourth quarter and full year 2021 financial results and business highlights.Follow. WALTHAM, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the pricing of ...
Open this page to get detailed information about APLS traded on NasdaqGS exchange in United States. ... NASDAQ DM Ex Japan Large Mid CaNQDMXJPLMAUD, 2100.38 AUD ...Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Apellis Pharmaceuticals Inc (Symbol: APLS), where a total of 7,621 contracts have ...2 Apellis Pharmaceuticals Inc (NASDAQ: APLS) stock’s 52-week price range is $33 – $94. The share price of Apellis Pharmaceuticals Inc (NASDAQ: APLS) has plunged by a huge 60% in the past month, adding to the woes of its shareholders over the last year. Moreover, the stock has not done well, decreasing by 33.33% in the last six months.Stock Quote & Chart. NASDAQ: APLS. $61.58. Dec 1, 2023 4:00 PM EST. Change. +7.71 (+14.31%). Volume. 5,431,264. Today's Open. $53.99. Previous Close. $53.87.
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WALTHAM, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved t...
APLS NASDAQ. APLS NASDAQ. APLS NASDAQ. APLS NASDAQ. Market closed Market closed. No trades. See on Supercharts. Overview News Ideas Financials Technicals . Forecast . Price target. 71.19 0.00 0.00%. The 16 analysts offering 1 year price forecasts for APLS have a max estimate of — and a min estimate of —. Analyst rating. Based on 17 …
Apellis Pharmaceuticals (NASDAQ:APLS) raised ~$150m via its initial public offering ("IPO") back in November 2017, issuing just over 10.7m share at a price of $14 per share. The company described ...Find the latest Insider Activity data for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.NASDAQ:APLS Long Term Investor Notice: Investigation of Potential Wrongdoing at Apellis Pharmaceuticals, Inc. San Diego, CA -- (SBWIRE) -- 11/14/2023 -- Certain directors of Apellis Pharmaceuticals, Inc. are under investigation on behalf of current long-term investors in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) concerning potential …Noteworthy Monday Option Activity: BILL, APLS, CVNA. October 09, 2023 — 03:23 pm EDT. Written by BNK Invest for BNK Invest ->. Looking at options trading activity among components of the Russell ...Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin ...NASDAQ: APLS. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Apellis Pharmaceuticals Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. ... NASDAQ: Apellis Pharmaceuticals Inc Performance. USD USD; Diluted EPS (TTM)-5.23 …Find the latest Financials data for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.
Funds + ETFs. After-Hours Quotes. See All Market Activity->. News + Insights.Real time Apellis Pharmaceuticals (APLS) stock price quote, stock graph, news & analysis. WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the closing ...Cash and cash equivalents of $765 million as of March 31, 2023; expected cash runway into Q1 2025. WALTHAM, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its first quarter 2023 financial results and business …Over the past 3 months, 10 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:APLS) stock. These analysts are typically employed by large Wall Street banks and tasked with ...APLS STOCK Price - Apellis Pharmaceuticals Inc NASDAQ USA Technical Analysis, Forecast, Important Levels, Latest News, Interactive Charts.WALTHAM, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that five abstracts ...
NASDAQ: APLS. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Apellis Pharmaceuticals Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. ... NASDAQ: Apellis Pharmaceuticals Inc Performance. USD USD; Diluted EPS (TTM)-5.23 …
Nov 14, 2023 · NASDAQ:APLS Long Term Investor Notice: Investigation of Potential Wrongdoing at Apellis Pharmaceuticals, Inc. An investigation on behalf of current long term investors in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) shares over possible breaches of fiduciary duty by certain officers and directors was announced. Nov 19, 2023 · Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin ... WALTHAM, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company ...Jul 6, 2023 · Fintel reports that on July 21, 2023, HC Wainwright & Co. maintained coverage of Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy recommendation. Analyst Price Forecast Suggests 203.86% Upside. As ... Funds + ETFs. After-Hours Quotes. See All Market Activity->. News + Insights.WALTHAM Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved ...Number of Hedge Fund Shareholders: 36. The number of hedge funds long Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has ticked up steadily over each of the past four quarters, more than doubling ...WALTHAM, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...Apellis Pharmaceuticals, Inc. (“Apellis”) (NASDAQ:APLS) recently completed an upsized underwritten public offering of 10062500 shares of its common stock at ...CRESTWOOD, Ky. and WALTHAM, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...
WALTHAM, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced its second quarter 2020 financial results and business highlights.
WALTHAM Mass., July 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company ...
CRESTWOOD, Ky. and WALTHAM, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...Apellis Pharmaceuticals, Inc. (APLS) Up 9.2% Since Last Earnings Report: Can It Continue? Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. …WALTHAM Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved ...Nov 2, 2023 · Apellis Pharmaceuticals, Inc. APLS reported third-quarter 2023 loss of $1.17 per share, which was wider than the Zacks Consensus Estimate of a loss of 84 cents. The company had reported a loss of ... Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Apellis Pharmaceuticals Inc (Symbol: APLS), where a total of 7,621 contracts have ...Apellis Pharmaceuticals, Inc. Common Stock (APLS) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets.Since Friday, Apellis Pharmaceuticals Inc (NASDAQ:APLS) shares have plummeted around 50% after the stock came under pressure following the disclosure of safety events connected to Syfovre. Syfovre ...Find the latest Financials data for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com. 23 de ago. de 2023 ... Apellis Pharmaceuticals Inc (NASDAQ:APLS) jumped some 35% in Wednesday's deals after last night updating investors on an ongoing safety ...Follow. WALTHAM, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that four oral ...Cash and cash equivalents of $765 million as of March 31, 2023; expected cash runway into Q1 2025. WALTHAM, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its first quarter 2023 financial results and business …Market forces rained on the parade of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) shareholders today, when the analysts downgraded their forecasts for this year. There was a fairly draconian cut ...
APLS GAP FILL APLS just had a sell of due to bad results on trial. $20 gap formed on 9.10 & I've just entered a position for an eventual gap fill. Underlying @ entry 33.33 I'm a beginner so this is not advice. APLS just had a sell of due to bad results on trial. $20 gap formed on 9.10 & I've just entered a position for an eventual gap fill. Nov 16, 2023 · The public float for APLS is 97.66M, and at present, short sellers hold a 16.62% of that float. On November 16, 2023, the average trading volume of APLS was 2.69M shares. APLS) stock’s latest price update. Apellis Pharmaceuticals Inc (NASDAQ: APLS)’s stock price has plunge by 0.54relation to previous closing price of 48.14. WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its fourth quarter and ...Apellis Pharmaceuticals Insider Sold Shares Worth $444,620, According to a Recent SEC Filing. Nov. 21. MT. Mizuho Raises Price Target on Apellis Pharmaceuticals to $49 From $42, Keeps Neutral Rating. Nov. 13. MT. Goldman Sachs Initiates Apellis Pharmaceuticals at Buy Rating With $74 Price Target.Instagram:https://instagram. ngl energyoptions trading vs day tradingdbefshort vs long position Apellis Pharmaceuticals (NASDAQ: APLS ) shares plunged Monday on the back of a short report from Citron Research, which said the "happy days are over" for the company. The short-selling firm said it has "reason to believe that CEO Cedric Francois is not being honest with Wall St. about the report cases of vasculitis" regarding the …Under priority review status, the FDA has accepted Apellis Pharmaceuticals' (NASDAQ:APLS) marketing application seeking approval for pegcetacoplan for the treatment of paroxysmal nocturnal ... fidelity growth company fundxm plans With a volume of 1,248,030, the price of APLS is up 1.39% at $51.0. RSI indicators hint that the underlying stock may be approaching overbought. Next earnings … old quarters worth Analyst Price Forecast Suggests 156.95% Upside. As of July 6, 2023, the average one-year price target for Apellis Pharmaceuticals is 104.04. The forecasts range from a low of 76.76 to a high of ...View today's Apellis Pharmaceuticals Inc stock price and latest APLS news and analysis. Create real-time notifications to follow any changes in the live ...MarketWatch IBD DJIA 35285.12 0.30% S&P 500 4554.22 0.11% U.S. 10 Yr 4/32 Yield 4.426% 0.15% Sign In Apellis Pharmaceuticals Inc. APLS (U.S.: Nasdaq) Overview News Apellis Pharmaceuticals...